AKT inhibitors have been shown to downregulate the expression of osteoglycin (OGN), an oncogene implicated in meningioma growth, in vitro and to stabilize meningotheliomatous meningioma growth in the lung of a patient with multiple intra- and extra-cranial tumors (53, 54). The gene discussed is OGN; the disease is meningioma.